The research-oriented firm is actively engaged in exploring and developing treatments for various diseases. Presently, traumatic brain injury (TBI) stands out as a major global healthcare challenge. Among the entities addressing this issue is Halberd Corporation (OTC: HALB). In an announcement on November 15, the company disclosed ongoing discussions with Mississippi State University (MSU) regarding a potential extension of their six-month research agreement for an additional two years. It was highlighted that the extension would encompass projects yet to be specified by the company. Halberd’s decision to pursue this extension was influenced by the commendable performance of MSU in the TBI Nasal Spray project. Furthermore, the company acknowledged the professionalism, capabilities, and proficiency demonstrated by the MSU team throughout their collaboration on the project.
Halberd Corporation additionally mentioned that Dr. Russell Carr, the principal investigator for the study, maintained positive interpersonal connections with the scientific leadership within the company. This aspect played a role in the decision to prolong the agreement. The initial six-month inquiry into Halberd Corporation’s nasal spray yielded notably positive results. The company’s intention in extending the research collaboration with MSU is to achieve statistically significant findings regarding the efficacy of the nasal spray.
On October 4, the company shared another significant update concerning its nasal spray designed to mitigate traumatic brain injury (TBI). Halberd disclosed that the test results related to TBI mitigation at Mississippi State University (MSU) aligned with the positive outcomes observed in the initial proof-of-concept testing. The findings revealed a 25% decrease in neuron-specific enolase (NSE) and a 52.3% reduction in glial fibrillary acid protein (GFAP) levels compared to the control group. NSE serves as a biomarker indicating neuron damage and is considered a predictor of TBI outcomes. GFAP is a metric commonly used to signify ongoing neurodegeneration resulting from TBI. Reductions in both GFAP and NSE levels signify improved neurological outcomes following traumatic brain injury.
Halberd Corporation is optimistic about the potential of its nasal spray as a groundbreaking product in the treatment of traumatic brain injury (TBI). There’s a belief that this innovation could extend its efficacy to address various neurological conditions. The company emphasized its commitment to refining the formulation of the product to optimize outcomes. Furthermore, Halberd highlighted its anticipation of feedback from the Department of Defense regarding future strategies.
HALB stock closed up by 4.33% to $0.0047 in Thursday’s trading session. The stock has seen buying at a lower level on valuation comfort due to increased volume. Moreover, the stock has formed a notable base at around $0.004–$0.0045. Over the past 52 weeks, the stock has been trading within a range of $0.0032 to $0.0196.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com